Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

This study is examining whether reducing the dose of chemotherapy in older patients with advanced non-small cell lung cancer (NSCLC) affects how long they survive. It looks at real-world data from patients aged 65 and older whose cancer does not have targetable gene mutations. **You may be eligible if...** - You are 65 years or older - You have been confirmed to have Stage IV (widely spread) non-small cell lung cancer - Your cancer does not have EGFR mutations, ALK rearrangements, or ROS1 fusions - You have received at least one cycle of first-line chemotherapy **You may NOT be eligible if...** - Your first-line treatment was targeted therapy or immunotherapy used alone (not chemotherapy) - Your survival follow-up data is incomplete Talk to your doctor to see if this trial is right for you.